Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma

Published:2024-01 Issue:1 Volume:19 Page:29-39
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Camera Silvia^ORCID,Rimini Margherita,Rossari Federico,Tada Toshifumi,Suda Goki,Shimose Shigeo,Kudo Masatoshi,Yoo Changhoon,Cheon Jaekyung,Finkelmeier Fabian,Lim Ho Yeong,Presa José,Masi Gianluca,Bergamo Francesca,Salani Francesca,Marseglia Mariarosaria,Amadeo Elisabeth,Vitiello Francesco,Kumada Takashi,Sakamoto Naoya,Iwamoto Hideki,Aoki Tomoko,Chon Hong Jae,Himmelsbach Vera,Iavarone Massimo,Cabibbo Giuseppe,Montes Margarida,Foschi Francesco Giuseppe,Vivaldi Caterina,Lonardi Sara,Sho Takuya,Niizeki Takashi,Nishida Naoshi,Steup Christoph,Hirooka Masashi,Kariyama Kazuya,Tani Joji,Atsukawa Masanori,Takaguchi Koichi,Itobayashi Ei,Fukunishi Shinya,Tsuji Kunihiko,Ishikawa Toru,Tajiri Kazuto,Ochi Hironori,Yasuda Satoshi,Toyoda Hidenori,Ogawa Chikara,Nishimura Takashi,Hatanaka Takeshi,Kakizaki Satoru,Shimada Noritomo,Kawata Kazuhito,Hiraoka Atsushi,Tada Fujimasa,Ohama Hideko,Nouso Kazuhiro,Morishita Asahiro,Tsutsui Akemi,Nagano Takuya,Itokawa Norio,Okubo Tomomi,Imai Michitaka,Kosaka Hisashi,Naganuma Atsushi,Koizumi Yohei,Nakamura Shinichiro,Kaibori Masaki,Iijima Hiroko,Hiasa Yoichi,Persano Mara,Foti Silvia,Piscaglia Fabio,Scartozzi Mario,Cascinu Stefano,Casadei-Gardini Andrea

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11523-023-01029-6.pdf

Reference46 articles.

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90. https://doi.org/10.1056/NEJMoa0708857.

3. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. https://doi.org/10.1016/S1470-2045(08)70285-7.

4. Bruix J, Cheng AL, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. J Hepatol. 2017;67:999–1008. https://doi.org/10.1016/j.jhep.2017.06.026.

5. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–73. https://doi.org/10.1016/S0140-6736(18)30207-1.